MiMedx Group Inc
NASDAQ:MDXG

Watchlist Manager
MiMedx Group Inc Logo
MiMedx Group Inc
NASDAQ:MDXG
Watchlist
Price: 8.84 USD 18.34%
Market Cap: 1.3B USD
Have any thoughts about
MiMedx Group Inc?
Write Note

Intrinsic Value

The intrinsic value of one MDXG stock under the Base Case scenario is 6.57 USD. Compared to the current market price of 8.84 USD, MiMedx Group Inc is Overvalued by 26%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MDXG Intrinsic Value
6.57 USD
Overvaluation 26%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
MiMedx Group Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MDXG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MDXG?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about MiMedx Group Inc

Provide an overview of the primary business activities
of MiMedx Group Inc.

What unique competitive advantages
does MiMedx Group Inc hold over its rivals?

What risks and challenges
does MiMedx Group Inc face in the near future?

Summarize the latest earnings call
of MiMedx Group Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MiMedx Group Inc.

Provide P/S
for MiMedx Group Inc.

Provide P/E
for MiMedx Group Inc.

Provide P/OCF
for MiMedx Group Inc.

Provide P/FCFE
for MiMedx Group Inc.

Provide P/B
for MiMedx Group Inc.

Provide EV/S
for MiMedx Group Inc.

Provide EV/GP
for MiMedx Group Inc.

Provide EV/EBITDA
for MiMedx Group Inc.

Provide EV/EBIT
for MiMedx Group Inc.

Provide EV/OCF
for MiMedx Group Inc.

Provide EV/FCFF
for MiMedx Group Inc.

Provide EV/IC
for MiMedx Group Inc.

Show me price targets
for MiMedx Group Inc made by professional analysts.

What are the Revenue projections
for MiMedx Group Inc?

How accurate were the past Revenue estimates
for MiMedx Group Inc?

What are the Net Income projections
for MiMedx Group Inc?

How accurate were the past Net Income estimates
for MiMedx Group Inc?

What are the EPS projections
for MiMedx Group Inc?

How accurate were the past EPS estimates
for MiMedx Group Inc?

What are the EBIT projections
for MiMedx Group Inc?

How accurate were the past EBIT estimates
for MiMedx Group Inc?

Compare the revenue forecasts
for MiMedx Group Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MiMedx Group Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MiMedx Group Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of MiMedx Group Inc compared to its peers.

Compare the P/E ratios
of MiMedx Group Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing MiMedx Group Inc with its peers.

Analyze the financial leverage
of MiMedx Group Inc compared to its main competitors.

Show all profitability ratios
for MiMedx Group Inc.

Provide ROE
for MiMedx Group Inc.

Provide ROA
for MiMedx Group Inc.

Provide ROIC
for MiMedx Group Inc.

Provide ROCE
for MiMedx Group Inc.

Provide Gross Margin
for MiMedx Group Inc.

Provide Operating Margin
for MiMedx Group Inc.

Provide Net Margin
for MiMedx Group Inc.

Provide FCF Margin
for MiMedx Group Inc.

Show all solvency ratios
for MiMedx Group Inc.

Provide D/E Ratio
for MiMedx Group Inc.

Provide D/A Ratio
for MiMedx Group Inc.

Provide Interest Coverage Ratio
for MiMedx Group Inc.

Provide Altman Z-Score Ratio
for MiMedx Group Inc.

Provide Quick Ratio
for MiMedx Group Inc.

Provide Current Ratio
for MiMedx Group Inc.

Provide Cash Ratio
for MiMedx Group Inc.

What is the historical Revenue growth
over the last 5 years for MiMedx Group Inc?

What is the historical Net Income growth
over the last 5 years for MiMedx Group Inc?

What is the current Free Cash Flow
of MiMedx Group Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for MiMedx Group Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
MiMedx Group Inc

Current Assets 172.1m
Cash & Short-Term Investments 88.8m
Receivables 54m
Other Current Assets 29.3m
Non-Current Assets 71.8m
PP&E 9.3m
Intangibles 30.6m
Other Non-Current Assets 31.8m
Current Liabilities 41.9m
Accounts Payable 6.9m
Accrued Liabilities 28.6m
Other Current Liabilities 6.5m
Non-Current Liabilities 20.9m
Long-Term Debt 18m
Other Non-Current Liabilities 2.9m
Efficiency

Earnings Waterfall
MiMedx Group Inc

Revenue
342.8m USD
Cost of Revenue
-57m USD
Gross Profit
285.8m USD
Operating Expenses
-222.4m USD
Operating Income
63.4m USD
Other Expenses
18.6m USD
Net Income
82m USD

Free Cash Flow Analysis
MiMedx Group Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MDXG Profitability Score
Profitability Due Diligence

MiMedx Group Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

62/100
Profitability
Score

MiMedx Group Inc's profitability score is 62/100. The higher the profitability score, the more profitable the company is.

MDXG Solvency Score
Solvency Due Diligence

MiMedx Group Inc's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Long-Term Solvency
83/100
Solvency
Score

MiMedx Group Inc's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MDXG Price Targets Summary
MiMedx Group Inc

Wall Street analysts forecast MDXG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MDXG is 12.44 USD with a low forecast of 11.11 USD and a high forecast of 14.7 USD.

Lowest
Price Target
11.11 USD
26% Upside
Average
Price Target
12.44 USD
41% Upside
Highest
Price Target
14.7 USD
66% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MDXG?

Click here to dive deeper.

Dividends

MiMedx Group Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MDXG is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

MiMedx Group Inc Logo
MiMedx Group Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.3B USD

Dividend Yield

0%

Description

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 811 full-time employees. The company went IPO on 2007-08-20. The firm is focused on addressing unmet clinical needs in the areas of advanced wound care, surgical recovery applications, and musculoskeletal conditions. The Company’s primary platform technologies include EPIFIX, AMNIOFIX, EPICORD, and AMNIOCORD. The AMNIOFIX and EPIFIX are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. Its EPICORD and AMNIOCORD are tissue allografts derived from umbilical cord tissue. EPIFIX is a semi-permeable, protective barrier allograft comprised of dehydrated human amnion/chorion membrane that may be used in the treatment of chronic wounds, including diabetic foot ulcers (DFUs), venous leg ulcers (VLUs), and pressure ulcers. AMNIOFIX is used in surgical recovery applications including in the areas of spine, orthopedic, sports medicine and urologic.

Contact

GEORGIA
Marietta
1775 W Oak Commons Ct
+17706519100.0
mimedx.com

IPO

2007-08-20

Employees

811

Officers

CEO & Director
Mr. Joseph H. Capper
Chief Financial Officer
Mr. Douglas C. Rice CPA
General Counsel & Chief Administrative Officer
Mr. William F. Hulse IV
Senior Vice President of Operations & Procurement
Mr. Scott M. Turner
Head of Investor Relations
Mr. Matthew M. Notarianni
Senior VP & Chief Compliance Officer
Mr. Mark P. Graves
Show More
Vice President of Investor Relations & Corporate Strategic Communications
Hilary Dixon
Chief Human Resources Officer
Ms. Kate Surdez
Chief Medical Officer
Dr. David H. Mason Jr.
President of Regenerative Medicine & Biologics Innovation
Dr. Robert Benjamin Stein M.D., Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MDXG stock?

The intrinsic value of one MDXG stock under the Base Case scenario is 6.57 USD.

Is MDXG stock undervalued or overvalued?

Compared to the current market price of 8.84 USD, MiMedx Group Inc is Overvalued by 26%.

Back to Top